News & Events about Denali Therapeutics Inc.
Program uses Denalis Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagementCAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Biogen Inc.(Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) ...
Latest Ratings for DNLI
DateFirmActionFromTo Jan 2022Morgan StanleyMaintainsOverweight Sep 2021OppenheimerInitiates Coverage OnOutperform Aug 2021Morgan StanleyMaintainsOverweight
View More Analyst Ratings for DNLI
View the Latest Analyst Ratings
read more...
Data show that DNL343 is generally well-tolerated at doses that demonstrate robust inhibition of biomarkers associated with the integrated stress response (ISR)Clinical pharmacokinetic and ISR pharmacodynamic data, along with preclinical data, are consistent with extensive CNS distribution and ...
Denali Therapeutics Inc. (NASDAQ:DNLI Get Rating) Stock analysts at Wedbush increased their Q1 2023 earnings per share (EPS) estimates for shares of Denali Therapeutics in a research report issued on Tuesday, February 28th. Wedbush analyst L. Chico now expects that the company will earn ($0.69) per ...
Ticker Report
2 months ago
Denali Therapeutics Inc. (NASDAQ:DNLI Get Rating) Investment analysts at SVB Leerink dropped their Q1 2023 earnings per share estimates for Denali Therapeutics in a research report issued to clients and investors on Monday, February 27th. SVB Leerink analyst M. Goodman now forecasts ...